<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>316</serviceExecutionTime><Drug id="40632"><DrugName>IGF-1 receptor tyrosine kinase inhibitor, Ontogen</DrugName><DrugSynonyms><Name><Value>IGF-1 receptor tyrosine kinase inhibitor, Ontogen</Value></Name><Name><Value>insulin-like growth factor 1 receptor kinase inhibitors, Ontogen</Value></Name></DrugSynonyms><CompanyOriginator id="22709">Ontogen Corp</CompanyOriginator><CompaniesSecondary><Company id="22709">Ontogen Corp</Company></CompaniesSecondary><CrossReferences><SourceEntity id="22709" type="Company"><TargetEntity id="4296345305" type="organizationId">Ontogen Corp</TargetEntity></SourceEntity><SourceEntity id="276" type="ciIndication"><TargetEntity id="C61" type="ICD10"/><TargetEntity id="10060862" type="MEDDRA"/><TargetEntity id="D011471" type="MeSH"/><TargetEntity id="-405461207" type="omicsDisease"/><TargetEntity id="637" type="siCondition"/><TargetEntity id="5083" type="siCondition"/></SourceEntity><SourceEntity id="281" type="ciIndication"><TargetEntity id="L40" type="ICD10"/><TargetEntity id="10037153" type="MEDDRA"/><TargetEntity id="D011565" type="MeSH"/><TargetEntity id="-1735788310" type="omicsDisease"/><TargetEntity id="490" type="siCondition"/></SourceEntity><SourceEntity id="49" type="ciIndication"><TargetEntity id="C50" type="ICD10"/><TargetEntity id="10006279" type="MEDDRA"/><TargetEntity id="D001943" type="MeSH"/><TargetEntity id="-436099203" type="omicsDisease"/><TargetEntity id="588" type="siCondition"/></SourceEntity><SourceEntity id="3252" type="Action"><TargetEntity id="2556" type="Mechanism">Anti-CD221 (IGF-1R)</TargetEntity><TargetEntity id="1104" type="Mechanism">IGF-1R Inhibitors</TargetEntity><TargetEntity id="3642" type="Mechanism">Anti-IGF-1</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity></SourceEntity><SourceEntity id="PTGT-01033" type="ciTarget"><TargetEntity id="183017565234803" type="siTarget">Insulin-like growth factor 1 receptor</TargetEntity><TargetEntity id="381" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="276">Prostate tumor</Indication><Indication id="281">Psoriasis</Indication><Indication id="49">Breast tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action><Action id="1545">Anticancer</Action><Action id="15184">Systemic antipsoriatic product</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>D5B</Code><Name>SYSTEMIC ANTIPSORIASIS PRODUCTS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-28T06:15:24.000Z</LastModificationDate><ChangeDateLast>2008-08-11T12:07:07.000Z</ChangeDateLast><AddedDate>2002-07-15T16:07:04.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="22709" linkType="Company"&gt;Ontogen&lt;/ulink&gt; was investigating inhibitors insulin-like growth factor 1 (IGF-1) receptor tyrosine kinase, for the potential treatment of breast cancer, prostate tumor and psoriasis [&lt;ulink linkID="457902" linkType="reference"&gt;457902&lt;/ulink&gt;]; however, by May 2006, Ontogen had fortfeited its rights to trade and  all research and development activities were presumed to be  discontinued [&lt;ulink linkID="933319" linkType="Reference"&gt;933319&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="22709">Ontogen Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="276">Prostate tumor</Indication><StatusDate>2006-05-26T00:00:00.000Z</StatusDate><Source id="933319" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22709">Ontogen Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="281">Psoriasis</Indication><StatusDate>2006-05-26T00:00:00.000Z</StatusDate><Source id="933319" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22709">Ontogen Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="49">Breast tumor</Indication><StatusDate>2006-05-26T00:00:00.000Z</StatusDate><Source id="933319" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="22709">Ontogen Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate>2002-07-15T00:00:00.000Z</StatusDate><Source id="457902" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22709">Ontogen Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate>2002-07-15T00:00:00.000Z</StatusDate><Source id="457902" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22709">Ontogen Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2002-07-15T00:00:00.000Z</StatusDate><Source id="457902" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01033"><Name>Insulin-like growth factor 1 receptor</Name><SwissprotNumbers><Swissprot>P08069</Swissprot><Swissprot>P24062</Swissprot><Swissprot>Q05688</Swissprot><Swissprot>Q29000</Swissprot><Swissprot>Q60751</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>